Innovators in Complex Carbohydrate Chemistry
We are a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds to address unmet medical needs in diabetes.
View PipelineBoston Therapeutics, Inc. (BTHE)
A non-toxic, chewable diabetic solution
BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications.
The cell bodyguard
IPOXYN™, is an injectable Rx for prevention of necrosis and treatment of ischemic conditions which may lead to necrosis.
About Boston Therapeutics
We are a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds to address unmet medical needs in diabetes.
